Please login to the form below

Not currently logged in
Email:
Password:

CEVEC and Catalent partner on cell lines

CEVEC Pharmaceuticals and Catalent Pharma Solutions have launched a joint commercial cell line development service for pharma and biotech customers worldwide

CEVEC Pharmaceuticals and Catalent Pharma Solutions have launched a joint commercial cell line development service for pharma and biotech customers worldwide. 

The offering combines the benefits of CEVEC's human cell line, CAP-Technology, with Catalent's unique GPEx (Gene Product Expression) Technology to generate high expressing stable human cell lines in a much shorter timeframe than traditional methods.


Wolfgang Kintzel, managing director of CEVEC, said: "The combined offering is a very compelling value proposition for clients looking to outsource cell line development and potential downstream cGMP upscaling while looking for the highest quality using a human cell line."

16th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics